Peptilogics, Pittsburgh, Pennsylvania, USA.
Arthritis and Arthroplasty Design Group, Department of Orthopedic Surgery, University of Pittsburghgrid.21925.3d, Pittsburgh, Pennsylvania, USA.
Microbiol Spectr. 2021 Dec 22;9(3):e0187921. doi: 10.1128/Spectrum.01879-21. Epub 2021 Nov 24.
PLG0206 is an engineered antimicrobial peptide that has completed phase 1 clinical studies. A prospective study was completed on explanted implants from chronic periprosthetic joint infections ( = 17). At a concentration of 1 mg/mL for 15 min, there was a mean 4-log reduction (range, 1 to 7) in the bacterial CFU identified from the implants. Chronically infected prosthetics of the knee were exposed to PLG0206, an engineered antimicrobial peptide, at a concentration of 1 mg/mL for 15 min. A mean 4-log reduction (range, 1 to 7) in the number of bacteria occurred, which may translate to improved clinical outcomes for persons with prosthetic joint infection of the knee.
PLG0206 是一种经过工程设计的抗菌肽,已完成 1 期临床研究。对 17 例慢性人工关节周围感染( = 17)取出的植入物进行了前瞻性研究。在浓度为 1mg/mL、作用 15min 的条件下,植入物中细菌的 CFU 数量平均减少了 4 个对数级(范围为 1 至 7)。将浓度为 1mg/mL、作用 15min 的工程抗菌肽 PLG0206 作用于膝关节慢性感染的人工假体,细菌数量平均减少了 4 个对数级(范围为 1 至 7),这可能会改善膝关节人工关节感染患者的临床预后。